Moreover, in order to remove the metastatic effect of cancer, a biotechnology company named Aethlon Medical has developed an adjuvant therapy called HER2O-some, which decreases HER2-positive EXOs secreted by cancer cells in circulation and thus interrupts the progression of HER2-positive breast cancer. Here, ERBB2 is linked to breast cancer.